{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:03:59Z","timestamp":1787807039844,"version":"build-2784847793"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ajo.2025.03.023","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:09:58Z","timestamp":1742328598000},"page":"36-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study"],"prefix":"10.1016","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4603-826X","authenticated-orcid":false,"given":"Moiz","family":"Lakhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-1112","authenticated-orcid":false,"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-0759","authenticated-orcid":false,"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-6472","authenticated-orcid":false,"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.03.023_bib0001","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/OPTH.S221094","article-title":"Intraoperative floppy iris syndrome: updated perspectives","volume":"14","author":"Christou","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.03.023_bib0002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/j.jcrs.0000000000001017","article-title":"Factors predisposing to intraoperative floppy-iris syndrome: an up-to-date meta-analysis","volume":"48","author":"Christou","year":"2022","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0003","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urology.2010.01.025","article-title":"Intraoperative floppy iris syndrome: facts for the urologist","volume":"76","author":"Yaycioglu","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ajo.2025.03.023_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcjo.2024.06.006","article-title":"Prevalence and prediction of intraoperative floppy iris syndrome in patients with pseudoexfoliation syndrome","volume":"60","author":"Eremenko","year":"2024","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.023_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcrs.2018.08.029","article-title":"The role of sex in intraoperative floppy-iris syndrome","volume":"45","author":"Tzamalis","year":"2019","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.023_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5507\/bp.2022.042","article-title":"Floppy iris syndrome associated with specific medication intake: a narrative review","volume":"167","author":"Maluskova","year":"2023","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.023_bib0007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3928\/15428877-20090430-02","article-title":"Clinical factors associated with floppy iris signs: a prospective study from two centers","volume":"40","author":"Altan-Yaycioglu","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.023_bib0008","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/bjo.2008.138826","article-title":"Possible mechanism of intraoperative floppy iris syndrome: a clinicopathological study","volume":"92","author":"Goseki","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.023_bib0009","first-page":"502","article-title":"The adrenergic receptors of the intraocular muscles of the human eye","volume":"15","author":"van Alphen","year":"1976","journal-title":"Invest Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0031-6997(25)06845-0","article-title":"International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update","volume":"47","author":"Hieble","year":"1995","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.023_bib0011","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/02713683.2017.1359306","article-title":"The effects of systemic alfuzosin and tamsulosin hydrochloride on choroidal thickness and pupil diameter sizes in cases with benign prostatic hyperplasia","volume":"42","author":"Dogan","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajo.2025.03.023_bib0012","first-page":"234","article-title":"Intraoperative floppy iris syndrome: pathophysiology, prevention, and treatment","volume":"107","author":"Flach","year":"2009","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.023_bib0013","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jcrs.2014.02.014","article-title":"Awareness of intraoperative floppy-iris syndrome among primary care physicians","volume":"40","author":"Doss","year":"2014","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.ajo.2025.03.023_bib0014","unstructured":"FDA Adverse Event Reporting System (FAERS) public dashboard. U.S. Food and Drug Administration. 2023. Accessed December 3, 2024. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"10.1016\/j.ajo.2025.03.023_bib0015","unstructured":"Postmarketing Adverse Event Reporting Compliance Program. U.S. Food and Drug Administration. 2024. Accessed December 4, 2024. https:\/\/www.fda.gov\/drugs\/surveillance\/postmarketing-adverse-event-reporting-compliance-program."},{"issue":"1","key":"10.1016\/j.ajo.2025.03.023_bib0016","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.023_bib0017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajo.2025.03.023_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.023_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29074","article-title":"Adverse drug events by sex after adjusting for baseline rates of drug use","volume":"6","author":"Rushovich","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.023_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.9249","article-title":"Adverse events associated with the use of sipuleucel-T reported to the US Food and drug administration's adverse event reporting system, 2010-2017","volume":"2","author":"Dores","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0021","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the Food and Drug Administration","volume":"23","author":"Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil\u2014free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajo.2025.03.023_bib0023","unstructured":"OpenVigil\u2014open tools for data-mining and analysis of pharmacovigilance data. Accessed July 8, 2024. https:\/\/openvigil.sourceforge.net\/."},{"key":"10.1016\/j.ajo.2025.03.023_bib0024","unstructured":"Center for Drug Evaluation and Research. FDA Adverse event reporting system (FAERS) public dashboard. U.S. Food and Drug Administration. 2023. Accessed July 8, 2024. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"issue":"6","key":"10.1016\/j.ajo.2025.03.023_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA\u2014inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2025.03.023_bib0026","unstructured":"FDA Surveillance Programs. Toolkit. 2020. Accessed December 7, 2024. https:\/\/toolkit.ncats.nih.gov\/module\/after-fda-approval\/after-fda-approval\/fda-surveillance-programs\/."},{"issue":"6","key":"10.1016\/j.ajo.2025.03.023_bib0027","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/pds.964","article-title":"Comparison of data mining methodologies using Japanese spontaneous reports","volume":"13","author":"Kubota","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.ajo.2025.03.023_bib0028","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"11","key":"10.1016\/j.ajo.2025.03.023_bib0029","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.023_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.023_bib0031","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12874-019-0754-4","article-title":"Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes","volume":"19","author":"Vickerstaff","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.023_bib0032","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcrs.2007.10.045","article-title":"Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles: possible model for intraoperative floppy-iris syndrome","volume":"34","author":"Palea","year":"2008","journal-title":"J Cataract Refract Surg"},{"issue":"11","key":"10.1016\/j.ajo.2025.03.023_bib0033","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/archophthalmol.2010.243","article-title":"Intraoperative floppy iris syndrome: report of a case and histopathologic analysis","volume":"128","author":"Panagis","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.023_bib0034","first-page":"158","article-title":"Intracameral epinephrine without the addition of intracameral lidocaine in the management of tamsulosin associated intraoperative floppy iris syndrome","volume":"166","author":"Fenicia","year":"2015","journal-title":"Clin Ter"},{"issue":"10","key":"10.1016\/j.ajo.2025.03.023_bib0035","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.ophtha.2012.04.028","article-title":"Intracameral phenylephrine 1.5% for prophylaxis against intraoperative floppy iris syndrome: prospective, randomized fellow eye study","volume":"119","author":"Lorente","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2025.03.023_bib0036","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1755-3768.2008.01442.x","article-title":"Intraoperative floppy iris syndrome (IFIS): a practical approach to medical and surgical considerations in cataract extractions","volume":"87","author":"Storr-Paulsen","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.023_bib0037","series-title":"Dose-related changes in iris dilator muscle with tamsulosin","author":"Prata","year":"2008"},{"key":"10.1016\/j.ajo.2025.03.023_bib0038","series-title":"Histopathologic features of the tamsulosin iris","author":"Santaella","year":"2008"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0039","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0301-4738.94057","article-title":"Floppy iris syndrome with oral imipramine: a case series","volume":"60","author":"Gupta","year":"2012","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.023_bib0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10792-018-0840-3","article-title":"Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study","volume":"39","author":"Kaczmarek","year":"2019","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.023_bib0041","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jcjo.2016.02.008","article-title":"Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs","volume":"51","author":"Matsuo","year":"2016","journal-title":"Can J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.023_bib0042","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.eye.6702914","article-title":"Intraoperative floppy-iris syndrome associated with chronic use of chlorpromazine","volume":"21","author":"Unal","year":"2007","journal-title":"Eye"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.023_bib0043","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.euroneuro.2009.07.005","article-title":"Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors","volume":"19","author":"Tanibuchi","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0044","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/j.1755-3768.2011.02132.x","article-title":"Risk factors for intraoperative floppy iris syndrome: a retrospective study","volume":"90","author":"Chatziralli","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.023_bib0045","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jcrs.2007.07.025","article-title":"Intraoperative floppy-iris syndrome and finasteride intake","volume":"33","author":"Issa","year":"2007","journal-title":"J Cataract Refract Surg"},{"issue":"7","key":"10.1016\/j.ajo.2025.03.023_bib0046","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jcrs.2011.04.013","article-title":"Finasteride-associated cataract and intraoperative floppy-iris syndrome","volume":"37","author":"Wong","year":"2011","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0047","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/ICU.0b013e3283360b7e","article-title":"Gender and glaucoma: what we know and what we need to know","volume":"21","author":"Vajaranant","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.023_bib0048","series-title":"Carbonic Anhydrase Inhibitors","author":"Aslam","year":"2023"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.023_bib0049","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms driving gender differences in asthma","volume":"17","author":"Fuseini","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.023_bib0050","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcrs.2019.01.034","article-title":"Angiotensin receptor inhibitors as main predisposing factor for intraoperative floppy iris syndrome in women","volume":"45","author":"Tzamalis","year":"2019","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.023_bib0051","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ophtha.2008.12.026","article-title":"Factors associated with intraoperative floppy iris syndrome","volume":"116","author":"Neff","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.023_bib0052","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ophtha.2010.08.039","article-title":"Risk factors for intraoperative floppy iris syndrome: a meta-analysis","volume":"118","author":"Chatziralli","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.023_bib0053","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/eye.2016.122","article-title":"Risk factors for intraoperative floppy iris syndrome: a prospective study","volume":"30","author":"Chatziralli","year":"2016","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.023_bib0054","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ICU.0000000000000322","article-title":"Floppy iris syndrome and cataract surgery","volume":"28","author":"Enright","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.023_bib0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jamaophthalmol.2021.4778","article-title":"Association between pentosan polysulfate sodium and retinal disorders","volume":"140","author":"McGwin Jr","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.023_bib0056","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.oftal.2022.08.002","article-title":"Impact of intraoperative floppy IRIS syndrome in cataract surgery by phacoemulsification: analysis of 622 cases","volume":"98","author":"Herranz Cabarcos","year":"2023","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"10.1016\/j.ajo.2025.03.023_bib0057","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241249908","article-title":"Exploring pharmacovigilance practices and knowledge among healthcare professionals: a cross-sectional multicenter study","volume":"12","author":"Hayek","year":"2024","journal-title":"SAGE Open Med"},{"issue":"104639","key":"10.1016\/j.ajo.2025.03.023_bib0058","article-title":"Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records","volume":"153","author":"Jeong","year":"2024","journal-title":"J Biomed Inform"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.023_bib0059","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Stat"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.023_bib0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.023_bib0061","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10654-020-00703-7","article-title":"Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking","volume":"36","author":"Shimonovich","year":"2021","journal-title":"Eur J Epidemiol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:56:03Z","timestamp":1777780563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":61,"alternative-id":["S0002939425001394"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.03.023","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}